Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
Abstract Background Urothelial bladder carcinoma accounts for around 3.9% cases of all the male cancers in India. Non-muscle-invasive bladder carcinoma (NMIBC) is predominant group which constitute approximately three fourth of the urothelial bladder cancer. Intravesical BCG immunotherapy is the cor...
Main Authors: | Vivek Sharma, Avinash P. S. Thakur, Vasantharaja Ramasamy, Pushpendra Kumar Shukla, Fanindra Singh Solanki, Arpan Choudhary, Prashant Patel |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2020-12-01
|
Series: | African Journal of Urology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12301-020-00099-6 |
Similar Items
-
Delayed cystectomy for T 1 G 3 TCC of urinary bladder managed initially by TURBT & intravesical immunotherapy (BCG + interferon) rationale & our result
by: N K Mohanty, et al.
Published: (2004-01-01) -
Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder
by: Eric K. Diner, et al.
Published: (2004-10-01) -
Protective role of intravesical BCG in COVID-19 severity
by: Héctor Gallegos, et al.
Published: (2021-03-01) -
Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
by: Suresh Bhat, et al.
Published: (2015-01-01) -
INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: K. M. Figurin
Published: (2014-07-01)